Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Intensity Therapeutics, Inc. ( (INTS) ) has shared an announcement.
On December 4, 2025, Intensity Therapeutics, Inc. announced an increase in the capacity of its ‘at-the-market’ offering program to $30 million, aimed at enhancing financial flexibility. This expansion allows the company to access capital efficiently, though there is no obligation to issue shares, and any utilization will depend on market conditions and strategic priorities.
The most recent analyst rating on (INTS) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Intensity Therapeutics, Inc. stock, see the INTS Stock Forecast page.
Spark’s Take on INTS Stock
According to Spark, TipRanks’ AI Analyst, INTS is a Underperform.
Intensity Therapeutics faces significant challenges typical of a pre-revenue biotech firm, including negative financial metrics and bearish technical indicators. While recent corporate announcements about cancer treatment progress are promising, they do not outweigh the financial and technical difficulties. The overall score reflects these challenges, positioning the stock at the lower end of the scoring range.
To see Spark’s full report on INTS stock, click here.
More about Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc. operates in the biotechnology industry, focusing on developing cancer therapies. The company is primarily involved in creating innovative treatments designed to enhance the effectiveness of cancer immunotherapy.
Average Trading Volume: 30,252,539
Technical Sentiment Signal: Hold
Current Market Cap: $21.4M
For a thorough assessment of INTS stock, go to TipRanks’ Stock Analysis page.